Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479671 · ClinicalTrials.gov registry record · Early Phase 1
Low Dose Fat-Induced Insulin Resistance
A Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03479671: Completed Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance, sponsored by University of Pennsylvania.
NCT03479671 is a Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance that has completed, run by University of Pennsylvania. The registered enrollment target is 9 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03479671, a Early Phase 1 study of Diabetes Mellitus, Type 2 and Insulin Resistance, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably causes mild insulin resistance will be selected for use in future studies.
Primary Outcome
Rate of Glucose Disposal (mg/kg/min)
Conditions Studied
Interventions
- DRUG Intralipid, 20% Intravenous Emulsion
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2024-11-19 |
| Phase | Early Phase 1 |
What the finished NCT03479671 record still lists
NCT03479671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Intralipid, 20% Intravenous Emulsion is the first listed.
NCT03479671 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03479671 about?
NCT03479671 is a clinical study titled "Low Dose Fat-Induced Insulin Resistance". The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably ca...
What is the current status of trial NCT03479671?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2020-01-01. Estimated completion is 2024-11-19.
What conditions does trial NCT03479671 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity.
What interventions are being tested in trial NCT03479671?
The interventions under investigation include: Intralipid, 20% Intravenous Emulsion (DRUG).
Who is sponsoring clinical trial NCT03479671?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03479671 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03479671's enrollment target sits among peer trials
9 345th of 348 higher than 3 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I
COMPLETED · Early Phase 1
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI